Creg J. Workman

Active 2002–2025

69
Papers
23,990
Citations
53
h-index
67
i10-index

Citations

Citations per year for Creg J. Workman1998: 1 citations2002: 1 citations2003: 5 citations2004: 19 citations2005: 48 citations2006: 25 citations2007: 56 citations2008: 111 citations2009: 203 citations2010: 222 citations2011: 241 citations2012: 236 citations2013: 222 citations2014: 205 citations2015: 265 citations2016: 264 citations2017: 336 citations2018: 326 citations2019: 959 citations2020: 1,023 citations2021: 1,154 citations2022: 1,079 citations2023: 894 citations2024: 1,577 citations2025: 857 citations2026: 37 citations1999–2001: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,132 citing papers, 29.2% of this breakdownChina: 1,944 citing papers, 18.1% of this breakdownUnited Kingdom: 599 citing papers, 5.6% of this breakdownGermany: 588 citing papers, 5.5% of this breakdownJapan: 343 citing papers, 3.2% of this breakdownItaly: 326 citing papers, 3% of this breakdownAustralia: 324 citing papers, 3% of this breakdownFrance: 307 citing papers, 2.9% of this breakdownCanada: 299 citing papers, 2.8% of this breakdownSwitzerland: 219 citing papers, 2% of this breakdownSouth Korea: 212 citing papers, 2% of this breakdownSpain: 199 citing papers, 1.9% of this breakdown
0%29.2%Other 20.8%

Fields

  • Medicine45.7%
  • Immunology and Microbiology34%
  • Biochemistry, Genetics and Molecular Biology14.5%
  • Neuroscience3%
  • Engineering1.2%
  • Agricultural and Biological Sciences0.3%
  • Other1.3%

Topics

  • Immune Cell Function and Interaction12.5%
  • Cancer Immunotherapy and Biomarkers9.9%
  • T-cell and B-cell Immunology7.4%
  • Immunotherapy and Immune Responses7.3%
  • CAR-T cell therapy research5.4%
  • Immune cells in cancer3.5%
  • Other54%

Coauthors

All papers

Open in search
  1. How regulatory T cells work

    Authors: , , - Nature reviews. Immunology 2008 cited by 3,374

  2. Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

    Authors: , , , , , , , , , , , , , , , , , , , , - Cancer Research 2011 cited by 1,645

  3. Interferon-γ: teammate or opponent in the tumour microenvironment?

    Authors: , , - Nature reviews. Immunology 2021 cited by 578

  4. LAG-3 as the third checkpoint inhibitor

    Authors: , , - Nature Immunology 2023 cited by 323

  5. Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion

    Authors: , , , , , , , , , , , , , , , , , , - Nature Immunology 2019 cited by 535

  6. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

    Authors: , , , , , , , , , - Nature Immunology 2008 cited by 2,058

  7. The inhibitory cytokine IL-35 contributes to regulatory T-cell function

    Authors: , , , , , , , , , - Nature 2007 cited by 2,022

  8. Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8+ T Cell-Derived Interferon-γ

    Authors: , , , , , , , , , , , , , , , - Immunity 2019 cited by 352

  9. Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity

    Authors: , , , , , , , , , , , , , , , , , - Cell 2017 cited by 624

  10. Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Han Seok Ko, Ted M. Dawson - Science 2016 cited by 758

  11. Therapeutic targeting of regulatory T cells in cancer

    Authors: , , , , - Trends in cancer 2022 cited by 223

  12. Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor

    Authors: , , , , - Seminars in Immunology 2019 cited by 407

  13. Role of LAG-3 in Regulatory T Cells

    Authors: , , , , , , , , , , , , , - Immunity 2004 cited by 1,299

  14. LAG3 associates with TCR–CD3 complexes and suppresses signaling by driving co-receptor–Lck dissociation

    Authors: , , , , , , , , , , , - Nature Immunology 2022 cited by 208

  15. LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity

    Authors: , , , , , , , , , , , , , , , , , , , - Cell 2024 cited by 260

  16. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity

    Authors: , , , , , , , , , , , , , - Cell 2024 cited by 169

  17. Stability and function of regulatory T cells is maintained by a neuropilin-1–semaphorin-4a axis

    Authors: , , , , , , , , , , , - Nature 2013 cited by 590

  18. Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment

    Authors: , , , - Frontiers in Immunology 2021 cited by 184

  19. Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-3

    Authors: , , - The Journal of Immunology 2002 cited by 387

  20. IL-35-mediated induction of a potent regulatory T cell population

    Authors: , , , , , , , , , , , , , , , - Nature Immunology 2010 cited by 852

  21. Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy

    Authors: , , , , - Journal for ImmunoTherapy of Cancer 2020 cited by 144

  22. Autoreactive CD8+ T cells are restrained by an exhaustion-like program that is maintained by LAG3

    Authors: , , , , , , , , , , , , , , - Nature Immunology 2022 cited by 104

  23. Treg-Cell-Derived IL-35-Coated Extracellular Vesicles Promote Infectious Tolerance

    Authors: , , , , , , , , , , , , , , , , - Cell Reports 2020 cited by 159

  24. Interleukin-35 Limits Anti-Tumor Immunity

    Authors: , , , , , , , , , - Immunity 2016 cited by 309